Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.54 | 1.00 | 0.23 | -0.59 |
| FCF Yield | -2.24% | -3.72% | -3.62% | -4.06% |
| EV / EBITDA | -37.78 | -22.12 | -32.99 | -16.87 |
| Quality | ||||
| ROIC | -12.35% | -14.35% | -13.17% | -19.21% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.88 | 1.26 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 17.93% | 31.39% | -3.60% | -50.93% |
| Safety | ||||
| Net Debt / EBITDA | 6.13 | 2.78 | 3.71 | 2.57 |
| Interest Coverage | -16.81 | -21.61 | -21.57 | -35.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -252.29 |